Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.85 |
| ▸ | GAA | P10253 | 3/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | PHGDH | O43175 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153976 | 0.80 | MAPT (0.70) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL28322333 | 0.74 | MAPT (0.69) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL15911569 | 0.73 | MAPT (0.67) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL3730926 | 0.73 | MAPT (0.61) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL30301697 | 0.73 | MAPT (0.61) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL6629173 | 0.69 | MAPT (0.65) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL30301712 | 0.69 | MAPT (0.65) | CCR6HTTGAATDP1CYP2C9 | |
| SCHEMBL3679927 | 0.69 | TAAR1 (0.72) | — | |
| SCHEMBL1265183 | 0.69 | MAPT (0.68) | CCR6HTTTDP1CYP2C9CYP2C19 | |
| SCHEMBL4254513 | 0.69 | TAAR1 (0.79) | HTTGAAL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | CCR6 1153/4885HTT 2106/4885GAA 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.